Skip to contentP
Pure Bioscience, Inc.
P
PUREPure Bioscience, Inc. Q2 2020 · 10-Q
Revenue$349.00K$349.00K−11.4% vs Q2 2019 Net Income-$666.00K-$666.00KN/M vs Q2 2019 EPS Diluted-$0.01-$0.01N/M vs Q2 2019 The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pure Bioscience, Inc. · CIK 1006028 · Engraved from SEC EDGAR
Operating Cash Flowderived-$614,000N/M Margins · derivedGross margin59.3%
Operating margin-190.0%+137.9 pt vs Q2 2019
Net margin-190.8%+138.1 pt vs Q2 2019
ended Jan 31, 2020 · filed Mar 12, 2020 · 41 d after period end